Advaxis — Investor Presentation (January 2014)
27 slides from Advaxis's investor presentation, Jan 15, 2014
Slide 1: Corporate Presentation: Empowering the immune system from within
2013 Advaxis, Inc. | NASDAQ:ADXS Ticker: ADXS Corporate Presentation Empowering the immune system from within™
Slide 2: Forward Looking Statements
2013 Advaxis, Inc. | NASDAQ:ADXS Forward Looking Statements This presentation contains forward - looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expecta
Slide 3: Why Invest in Advaxis?
2013 Advaxis, Inc. | NASDAQ:ADXS Why Invest in Advaxis? Proprietary cancer immunotherapy platform technology -- hottest area of cancer research • Live attenuated bacteria stimulate the immune system to view the tumor as a bacterial infection for elimination -- No other technology has the same capabi
Slide 4: Anticipated Milestones
2013 Advaxis, Inc. | NASDAQ:ADXS 1H 2014 • Execute second ex - US HPV deal to market dominate player • Partner ADXS - cHER2 for animal - health indications • Conduct FDA EOP2 meeting for ADXS - HPV in recurrent cervical cancer • Initiate Phase 1/2 high - dose study in recurrent cervical cancer • Dos
Slide 5: Four Essentials of Cancer Immunotherapy
2013 Advaxis, Inc. | NASDAQ:ADXS Four Essentials of Cancer Immunotherapy No other technology integrates all of these elements into a single, well - tolerated, low cost to manufacture, and easy to administer immunotherapy 5 Access to Antigen Presenting Cells (APCs) to direct and target the immune res
Slide 6: Advaxis Approach: Elements in Action
2013 Advaxis, Inc. | NASDAQ:ADXS Advaxis Approach: 4 Elements in 1 6 Access APC, Secrete LLO - TAA, MHC1 CD8 T - cell Expansion, Over - ride Checkpoints Chemokines, Tumor Infiltration Decrease Treg, MDSCs, Tumor Cell Lysis 1 2 3 4
Slide 7: Proprietary Technology Platform Fuels Robust Clinical Pipeline
2013 Advaxis, Inc. | NASDAQ:ADXS +Icahn School of Medicine at Mount Sinai & Cancer Research UK ++BrUOG: Brown University Oncology Group Projected 2014 Product Indication Pre Phase 1 Phase 2 Phase 3 Cervical ADXS - HPV Cervical Head and Neck*+ Anal*++ ADXS - PSA Prostate ADXS - cHER2 Breast Animal -
Slide 8: Advaxis Platform Yields Numerous Drug Candidates
2013 Advaxis, Inc. | NASDAQ:ADXS Advaxis Platform Yields Numerous Drug Candidates 8 Tumor Antigen Disease Status HPV - E7 Cervical , Head and Neck, Others Phase 2 PSA Prostate Pre - IND Her2/Neu BrCa, Gastric, Esophageal Pre - IND/Phase 1 Veterinary Survivin Lymphoma, Pan - Tumor Antigen Pre - Veter
Slide 9: Global Opportunity for ADXS-HPV
2013 Advaxis, Inc. | NASDAQ:ADXS Global Opportunity for ADXS - HPV • HPV has a causative role in 5% of cancers worldwide • 80% of sexually active Americans will have contracted at least one strain of HPV by age 50 per the CDC • Current vaccines prevent infection by 2 (out of 15) oncogenic high - ris
Slide 10: Need for ADXS-HPV in cervical cancer
2013 Advaxis, Inc. | NASDAQ:ADXS Need for ADXS - HPV in cervical cancer • 99% of cervical cancers caused by HPV • A highly aggressive malignancy • Poor prognosis • No standard of care • Traditional cancer therapy ineffective ADXS - HPV Opportunity in Cervical Cancer Over 500 doses administered to 20
Slide 11: Phase 2 Clinical Trial Overview
2013 Advaxis, Inc. | NASDAQ:ADXS ADXS - HPV Phase 2 Clinical Trial Overview • Multi - center Phase 2 trial conducted in India • Patients with recurrent cervical cancer • Failed previous treatments, ECOG 0 - 2, majority with aggressive disease • Single agent activity with a single cycle of ADXS - HPV
Slide 12: Phase 2 Recurrent Cervical Cancer Study Design
2013 Advaxis, Inc. | NASDAQ:ADXS 3m 6m 9m 12m 18m Phase 2 Recurrent Cervical Cancer Study Design 12 ADXS - HPV +/ - Cisplatin (N = 110) Arm A N = 55 ADXS - HPV Only Arm B N = 55 ADXS - HPV +Cisplatin Treatment Follow - up Phase Scans ADXS ADXS ADXS ADXS ADXS ADXS 3m 6m 9m 12m 18m R ADXS C C C C C AD
Slide 13: Phase 2 Best Response Data
2013 Advaxis, Inc. | NASDAQ:ADXS ADXS - HPV Phase 2 Best Response Data Tumor reduction observed in patients infected with different high - risk HPV strains including HPV 16, 18, 31, 33 and 45, as expected. 13 6 Complete Responses 6 Partial Responses 35 Stable Disease
Slide 14: Landmark Survival
2013 Advaxis, Inc. | NASDAQ:ADXS Landmark Survival Overall survival observed with ADXS - HPV is consistent with an active agent in recurrent cervical cancer 14 Patients Overall (N=110) ADXS - HPV ALONE (N=56) ADXS - HPV + CISPLATIN (N=54) 9 - Month Survival 46% (51/110) 43% (24/56) 50% (27/54) 12 -
Slide 15: Prognostic Factors for Overall Survival in Cervical Cancer
2013 Advaxis, Inc. | NASDAQ:ADXS Prognostic Factors for Overall Survival in Cervical Cancer Trial Regimen N PS (%) 1 st line Prior Chem Prior RT % SAE Reported % CR Med. Surv. Resp. Durat. 12 - Mo. Surv. 18 - Mo. Surv. 24 - Mo. Surv. Petit 2013 LM - LLO - E7 - 15 (SITC #258) ADXS - HPV ADXS - HPV +
Slide 16: Next Steps for ADXS-HPV in Recurrent Cervical Cancer
2013 Advaxis, Inc. | NASDAQ:ADXS Next steps towards registration in this highly aggressive malignancy • Conduct EOP2 meeting with FDA, finalize Phase 3 protocols, submit SPA • Conduct 2 pivotal Phase 3 trials (multi - national trials with partner participation) • Conduct Phase 1/2 study with high do
Slide 17: Opportunity for ADXS-HPV in Head & Neck Cancer
2013 Advaxis, Inc. | NASDAQ:ADXS Opportunity for ADXS - HPV in Head & Neck Cancer 17 Need for ADXS - HPV in head and neck cancer • HPV - associated head & neck cancer is increasing at an epidemic rate due to changing sexual practices • 25%+ of head & neck cancer caused by HPV • Current therapies lea
Slide 18: Opportunity for ADXS-HPV in Anal Cancer
2013 Advaxis, Inc. | NASDAQ:ADXS Opportunity for ADXS - HPV in Anal Cancer Orphan Drug Designation Granted 18 Need for ADXS - HPV in anal cancer • 80 - 100% caused by HPV • Current therapies are toxic and have long - term side effects • No therapy for recurrent disease Clinical development • Discuss
Slide 19: Commercialization and Partnering Strategy
2013 Advaxis, Inc. | NASDAQ:ADXS Create long - term value for the Company by forming relationships with market dominant biopharmaceutical companies that validate our platform • Seeking partnerships that are aligned with the Company ’ s clinical and commercialization objectives Commercialization and
Slide 20: Licensing Agreement in Asia
2013 Advaxis, Inc. | NASDAQ:ADXS • Exclusive licensing agreement with Global BioPharma (GBP), funded by a group of investors led by Taiwan Biotech Company Ltd. (TBC) • TBC is one of the top 5 biopharmaceutical companies in Taiwan • Formed Global BioPharma (GBP) solely to focus on development and com
Slide 21: Animal-Health Program: ADXS-cHER2
2013 Advaxis, Inc. | NASDAQ:ADXS Immunotherapy targeting cancers overexpressing HER2 • Including breast cancer and others ADXS - cHER2 for the Treatment of Canine Osteosarcoma and Human Breast Cancers Animal - Health Program • Phase 1 data in canine osteosarcoma (CO) show encouraging survival in com
Slide 22: Animal-Health Products in Development
2013 Advaxis, Inc. | NASDAQ:ADXS Animal - Health -- Products in Development Canine Osteosarcoma (OS) • Approximately 8,000 - 20,000 dogs per year in the US • Highly aggressive mesenchymal tumor - - medium to large breeds • Standard of care treatment: amputation and post operative chemotherapy • High
Slide 23: ADXS31-164 Prolongs Survival in Dogs with Osteosarcoma
2013 Advaxis, Inc. | NASDAQ:ADXS All toxicities reported as Grade 1 and improved survival over case matched control 23 Survival of Data 4:Survival proportions 0 200 400 600 800 0 20 40 60 80 100 Legend Legend Days P e r c e n t s u r v i v a l ADXS31 - 164 Prolongs Survival in Dogs with OS ADXS 31 -
Slide 24: ADXS-PSA for the Treatment of Prostate Cancer
2013 Advaxis, Inc. | NASDAQ:ADXS ADXS - PSA for the Treatment of Prostate Cancer 24 Our approach • Target cells expressing PSA with our immunotherapy • Conducted a pre - IND meeting with the FDA to discuss the CMC, pharmacology, toxicology, and clinical plans for ADXS - PSA • Establish proof - of -
Slide 25: Why Invest in Advaxis?
2013 Advaxis, Inc. | NASDAQ:ADXS Why Invest in Advaxis? Proprietary cancer immunotherapy platform technology -- hottest area of cancer research • Live attenuated bacteria stimulate the immune system to view the tumor as a bacterial infection for elimination -- No other technology has the same capabi
Slide 26: Experienced Management Team & Board of Directors
2013 Advaxis, Inc. | NASDAQ:ADXS Experienced Management Team & Board of Directors Management Team Daniel J. O ’ Connor, Esq. President and Chief Executive Officer • 15 years of executive, legal, regulatory, compliance, manufacturing and quality experience in the biopharmaceutical industry • Former S
Slide 27: Advaxis, Inc. contact details
2013 Advaxis, Inc. | NASDAQ:ADXS 27 Advaxis, Inc. 305 College Road East Princeton, NJ 08540 T: 609.452.9813 [email protected] www.advaxis.com